SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control
Magdalene K. Montgomery, Jacqueline Bayliss, Camille J. Devereux, Ayenachew Bezawork‐Geleta, David Roberts, Cheng Huang, Ralf B. Schittenhelm, Andrew Ryan, Scott L. Townley, Luke A. Selth, Trevor J. Biden, Gregory R. Steinberg, Dorit Samocha‐Bonet, Ruth C. R. Meex, Matthew J. Watt
Abstract
mice, without adverse effects on adiposity, liver histopathology, or inflammation. Furthermore, circulating SMOC1 correlated with hepatic and systemic insulin sensitivity and was decreased in obese, insulin-resistant humans. Together, these findings identify SMOC1 as a potential pharmacological target for the management of glycemic control in type 2 diabetes.
Topics & Concepts
GlycemicMedicineControl (management)Diabetes mellitusBioinformaticsBiologyEndocrinologyComputer scienceArtificial intelligencePancreatic function and diabetesMetabolism, Diabetes, and CancerGlycosylation and Glycoproteins Research